also studied obesity-related MASLD and showed that ADSC treatment can reverse liver fat accumulation in obese mice and decrease TNF-α and IL-6 expression levels, improving MASLD symptoms (46). Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.